The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study
Open accessAbstract
BACKGROUND: Treatment for localized prostate cancer remains controversial. To our knowledge, there are no outcome studies from contemporary population-based cohorts that include data on stage, Gleason score, and serum levels of prostate-specific antigen (PSA). METHODS: In the National Prostate Cancer Register of Sweden Follow-up Study, a nationwide cohort, we identified 6849 patients aged 70 years or younger. Inclusion criteria were diagnosis with local clinical stage T1-2 prostate cancer from January 1, 1997, through December 31, 2002, a Gleason score of 7 or less, a serum PSA level of less than 20 ng/mL, and treatment with surveillance (including active surveillance and watchful waiting, n = 2021) or curative intent (including radical prostatectomy, n = 3399, and radiation therapy, n = 1429). Among the 6849 patients, 2686 had low-risk prostate cancer (ie, clinical stage T1, Gleason score 2-6, and serum PSA level of <10 ng/mL). The study cohort was linked to the Cause of Death Register, and cumulative incidence of death from prostate cancer and competing causes was calculated. RESULTS: For the combination of low- and intermediate-risk prostate cancers, calculated cumulative 10-year prostate cancer-specific mortality was 3.6% (95% confidence interval [CI] = 2.7% to 4.8%) in the surveillance group and 2.7% (95% CI = 2.1% to 3.45) in the curative intent group. For those with low-risk disease, the corresponding values were 2.4% (95% CI = 1.2% to 4.1%) among the 1085 patients in the surveillance group and 0.7% (95% CI = 0.3% to 1.4%) among the 1601 patients in the curative intent group. The 10-year risk of dying from competing causes was 19.2% (95% CI = 17.2% to 21.3%) in the surveillance group and 10.2% (95% CI = 9.0% to 11.4%) in the curative intent group. CONCLUSION: A 10-year prostate cancer-specific mortality of 2.4% among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Cited by
Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig, H. C., Lam, C., Maltz, A., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00375 · Cited by 573
Fenton, J. J., Weyrich, M. S., Durbin, S., Liu, Y., Bang, H., & Melnikow, J. (2018) · JAMA · doi:10.1001/jama.2018.3712 · Cited by 555
Zumsteg, Z. S., Spratt, D. E., Pei, I., Zhang, Z., Yamada, Y., Kollmeier, M., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.033 · Cited by 397
Sooriakumaran, P., Nyberg, T., Akre, O., Haendler, L., Heus, I., Olsson, M., Carlsson, S., Roobol, M. J., Steineck, G., & Wiklund, P. (2014) · BMJ · doi:10.1136/bmj.g1502 · Cited by 258
Metadata
- Authors
- Stattin, P., Holmberg, E., Johansson, J.-E., Holmberg, L., Adolfsson, J., Hugosson, J., & Sweden, O. B. O. T. N. P. C. R. (. O.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-18
- Volume
- 102
- Issue
- 13
- Pages
- 950-958
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2154675718
- Cited by
- 244
- References
- 2
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. https://app.cochat.ai/papers/10.1093/jnci/djq154
- The paper
- Stattin, P., Holmberg, E., Johansson, J.-E., Holmberg, L., Adolfsson, J., Hugosson, J., & Sweden, O. B. O. T. N. P. C. R. (. O. (2010). Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djq154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.